STRS Ohio’s Arcutis Biotherapeutics ARQT Stock Holding History

STRS Ohio’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$684K	Buy	26,100 +4,700	+22%	+$109K	﹤0.01%	973
2026 Q1	$504K	Hold	21,400	–	–	﹤0.01%	1080
2025 Q4	$621K	Hold	21,400	–	–	﹤0.01%	908
2025 Q3	$403K	Buy	21,400 +8,700	+69%	+$137K	﹤0.01%	1201
2025 Q2	$178K	Buy	+12,700	New	+$178K	﹤0.01%	1702
2020 Q2	–	Sell	-2,700	Closed	-$80K	–	2157
2020 Q1	$80K	Buy	+2,700	New	+$72.5K	﹤0.01%	1716

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

STRS Ohio's ARQT Position: Q2 2026 in Review

STRS Ohio increased its Arcutis Biotherapeutics (ARQT) stake by 22% in Q2 2026, buying an estimated $109K and bringing the position to 26,100 shares worth $684K. The position accounts for ﹤0.01% of the portfolio, ranked #973.

STRS Ohio first reported a position in ARQT in Q1 2020 and has held it in 6 quarters since. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

STRS Ohio held 26,100 shares of Arcutis Biotherapeutics worth $684K as of Q2 2026.
STRS Ohio bought 4,700 Arcutis Biotherapeutics shares in Q2 2026, an estimated $109K.
Arcutis Biotherapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #973 holding.
STRS Ohio first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 6 quarters since.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.